BlackRock, Inc. 13D and 13G filings for Y-mAbs Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-26 5:26 pm Purchase | 2023-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | BlackRock Inc. BLK | 2,917,080 6.700% | 338,304 (+13.12%) | Filing |
| 2023-02-01 4:54 pm Sale | 2022-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | BlackRock Inc. BLK | 2,578,776 5.900% | -188,584 (-6.81%) | Filing |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | BlackRock Inc. BLK | 2,767,360 6.300% | 348,780 (+14.42%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Y-mAbs Therapeutics, Inc. YMAB | BlackRock Inc. BLK | 2,418,580 6.000% | 452,462 (+23.01%) | Filing |